Next Article in Journal / Special Issue
Pediatric Dosing and Body Size in Biotherapeutics
Previous Article in Journal
Enhanced Dissolution and Oral Bioavailability of Piroxicam Formulations: Modulating Effect of Phospholipids
Open AccessReview

Drug Development for Pediatric Populations: Regulatory Aspects

Actelion Pharmaceuticals Ltd, Clinical Pharmacology, Gewerbestrasse 16, CH-4123 Allschwil, Switzerland
*
Author to whom correspondence should be addressed.
Pharmaceutics 2010, 2(4), 364-388; https://doi.org/10.3390/pharmaceutics2040364
Received: 15 October 2010 / Revised: 18 November 2010 / Accepted: 24 November 2010 / Published: 29 November 2010
Pediatric aspects are nowadays integrated early in the development process of a new drug. The stronger enforcement to obtain pediatric information by the regulatory agencies in recent years resulted in an increased number of trials in children. Specific guidelines and requirements from, in particular, the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) form the regulatory framework. This review summarizes the regulatory requirements and strategies for pediatric drug development from an industry perspective. It covers pediatric study planning and conduct, considerations for first dose in children, appropriate sampling strategies, and different methods for data generation and analysis to generate knowledge about the pharmacokinetics (PK) and pharmacodynamics (PD) of a drug in children. The role of Modeling and Simulation (M&S) in pediatrics is highlighted—including the regulatory basis—and examples of the use of M&S are illustrated to support pediatric drug development. View Full-Text
Keywords: pediatrics; children; pediatric drug development; pediatric legislation; health authorities; regulatory guidelines; PIP; clinical studies; Modeling and Simulation; PK/PD  modeling pediatrics; children; pediatric drug development; pediatric legislation; health authorities; regulatory guidelines; PIP; clinical studies; Modeling and Simulation; PK/PD  modeling
Show Figures

Figure 1

MDPI and ACS Style

Zisowsky, J.; Krause, A.; Dingemanse, J. Drug Development for Pediatric Populations: Regulatory Aspects. Pharmaceutics 2010, 2, 364-388. https://doi.org/10.3390/pharmaceutics2040364

AMA Style

Zisowsky J, Krause A, Dingemanse J. Drug Development for Pediatric Populations: Regulatory Aspects. Pharmaceutics. 2010; 2(4):364-388. https://doi.org/10.3390/pharmaceutics2040364

Chicago/Turabian Style

Zisowsky, Jochen; Krause, Andreas; Dingemanse, Jasper. 2010. "Drug Development for Pediatric Populations: Regulatory Aspects" Pharmaceutics 2, no. 4: 364-388. https://doi.org/10.3390/pharmaceutics2040364

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Search more from Scilit
 
Search
Back to TopTop